Dr Reddys Laboratories Share News - Latest Updates, Live News & More

Latest news about Dr Reddys Laboratories

Morgan Stanley Maintains Equal-weight Rating on Dr. Reddy's with ₹1,259 Target Price 4 days ago

Morgan Stanley has assigned an Equal-weight rating to Dr. Reddy's Laboratories with a target price of ₹1,259, citing the company's Health Canada approval for its first generic semaglutide. The approval strengthens the pharmaceutical company's GLP-1 and complex generics portfolio with an estimated revenue potential of approximately $200mn by FY27. However, the brokerage maintains a balanced outlook due to the current valuation of approximately 18x FY28E PE, suggesting the positive regulatory development is already reflected in the stock price.

Dr Reddy's Receives Notice of Compliance from Health Canada for Semaglutide 5 days ago

Delhi High Court Issues Warning to Dr. Reddy's Laboratories Over 'Olymviq' Trademark Compliance 5 days ago

Dr. Reddy's Laboratories Announces Q4FY26 Results Release on May 12, 2026 9 days ago

Dr. Reddy's Laboratories Board to Consider Final Dividend for FY 2025-26 Apr 16, 2026

More news about Dr Reddys Laboratories

16Apr 26

BofA Raises Dr. Reddy's Laboratories Target Price to ₹1,540, Maintains Buy Rating

Bank of America has raised Dr. Reddy's Laboratories' target price to ₹1,540 from ₹1,480 while maintaining its Buy rating. The brokerage cited diversified earnings drivers beyond semaglutide, with semaglutide serving as a key growth catalyst. BofA noted the company's resilience against geopolitical risks and highlighted cost-reduction measures that should keep margins above 20% even during revenue delays.

16Apr 26

Dr. Reddy's Laboratories Receives Regulatory Approval for Generic Oral Semaglutide Launch

Dr. Reddy's Laboratories has obtained regulatory approval to launch generic oral semaglutide, allowing the company to produce and distribute three drug formulations. This approval represents a strategic expansion of the company's diabetes treatment portfolio and positions it to compete in the oral semaglutide market with multiple formulation options.

15Apr 26

Citi Maintains Sell Rating on Dr. Reddy's Laboratories with ₹1,070 Target Price Following Brazil ANVISA Rejection

Citi has maintained its Sell rating on Dr. Reddy's Laboratories with a ₹1,070 target price following Brazil ANVISA's rejection of the company's Semaglutide generic Embeltah. The regulatory setback limits early launch participation opportunities amid 16 competing filings in the market. Additionally, Apotex's US tentative approval may provide competitive advantages over Dr. Reddy's in the Canadian market, further impacting the company's positioning in the diabetes medication segment.

14Apr 26

Dr. Reddy's Russian Subsidiary Receives Reduced Tax Penalty of RUB 9.27 Million

Dr. Reddy's Laboratories' Russian subsidiary has received a final tax penalty of RUB 9.27 million (INR 11.40 million) from Russian tax authorities on April 13, 2026, related to VAT levy on marketing services. The penalty represents a significant reduction from the original assessment of RUB 20.09 million (INR 24.50 million). The company has determined that this penalty will have no material impact on its financial operations or activities.

08Apr 26

Dr. Reddy's Laboratories Submits Q4 FY26 SEBI Compliance Certificate for Dematerialization Process

Dr. Reddy's Laboratories filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 8, 2026, covering the quarter ended March 31, 2026. The certificate, confirmed by registrar Bigshare Services Private Limited, validates that all securities dematerialization processes were completed within regulatory timelines. The filing demonstrates the company's adherence to SEBI depositories regulations and maintains transparency in securities management processes.

08Apr 26

Morgan Stanley Cuts Dr. Reddy's Target Price to ₹1,259 Amid Earnings Downgrades and North America Revenue Decline

Morgan Stanley maintains Equal Weight rating on Dr. Reddy's Laboratories while cutting target price to ₹1,259 from ₹1,285. The brokerage implemented earnings downgrades with FY26 EPS cut 10.7% and 5-6% reductions for FY27-28. North America revenue faces 21% decline in FY26 due to gRevlimid phase-out and GLP-1 uncertainty, though margins expected at 21-22.6% with recovery from FY28 led by semaglutide and biosimilars.

08Apr 26

Dr. Reddy's Laboratories Divests Wholly Owned Subsidiary Svaas Wellness for ₹2.23 Crore

Dr. Reddy's Laboratories has divested its wholly owned subsidiary Svaas Wellness Limited for ₹2.23 crore to Enspirited Technology Services Private Limited. The transaction was completed on April 7, 2026. Svaas Wellness contributed ₹28.5 crore turnover in FY 2025, representing 0.09% of consolidated turnover. The buyer is not affiliated with promoter groups, making it an arm's length transaction.

26Mar 26

Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan

Dr. Reddy's Laboratories allotted 3,675 equity shares on March 26, 2026, to eligible employees under its ADR Stock Options Scheme, 2007. The shares were issued at two different exercise prices - 575 shares at Re.1/- each and 3,100 shares at Rs. 735.80/- each. Following this allotment, the company's total issued shares increased to 83,46,57,970 with corresponding share capital of Rs. 83,46,57,970/-. The newly allotted shares rank pari passu with existing shares and comply with SEBI regulations.

25Mar 26

Delhi High Court Orders Dr Reddy's Laboratories to Stop Selling Olympiq Product

Delhi High Court has ordered Dr Reddy's Laboratories to stop selling its Olympiq product, as reported by NDTV Profit. The court directive represents a significant regulatory action that could impact the company's product availability and highlights potential legal or compliance challenges facing the pharmaceutical company.

25Mar 26

Dr. Reddy's Laboratories Amends Fair Disclosure Code for Price Sensitive Information

Dr. Reddy's Laboratories Limited has amended its Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information, approved by the Board on March 24, 2026. The updated code ensures SEBI compliance through comprehensive UPSI handling protocols, designating the Head of Investor Relations as Chief Investor Relations Officer. Key provisions include strict "need to know" information sharing, legitimate purpose frameworks for external disclosures, and mandatory maintenance of structured digital databases with eight-year retention requirements.

23Mar 26

Dr. Reddy's Laboratories Announces Board Meeting on May 12, 2026 for Q4FY26 Results

Dr. Reddy's Laboratories has scheduled a board meeting for May 12, 2026, to review audited financial results for Q4FY26 and FY26, with formal notifications sent to multiple stock exchanges including NSE, BSE, NYSE, and NSE IFSC. The company has implemented a trading window closure from March 25 to May 14, 2026, in compliance with SEBI insider trading regulations.

21Mar 26

Dr. Reddy's Laboratories Launches India's First DCGI-Approved Generic Semaglutide Injection 'Obeda®' for Type 2 Diabetes

Dr. Reddy's Laboratories has officially announced the launch of Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes management. The product, developed entirely in-house, demonstrated non-inferior efficacy in Phase III trials with 312 participants and is priced at INR 4,200.00 per month for both 2mg and 4mg strengths. The company plans global expansion and has developed SemaKare™ patient support system alongside metabolic centres of excellence across India.

17Mar 26

Dr. Reddy's Laboratories Receives GST Authority Tax Demand Orders Worth ₹2.20 Crore for FY 2019-22

Dr. Reddy's Laboratories received three GST Authority orders demanding penalties totaling ₹2,20,03,734 for FY 2019-20 to FY 2021-22, with the largest penalty of ₹2,19,48,944 for FY 2019-20. The orders were issued under section 74 of the TNGST Act, 2017, primarily on grounds that certain supplies are taxable in nature. The company has assessed no material impact on its operations and plans to evaluate filing appeals with the appellate authority.

13Mar 26

Dr. Reddy's Partner Immunet Discontinues TACTI-004 Phase III Trial for Eftilagimod Alfa Following Safety Review

Dr. Reddy's Laboratories disclosed that partner Immunet has discontinued the TACTI-004 Phase III trial for Eftilagimod Alfa in lung cancer following an Independent Data Monitoring Committee recommendation based on interim futility analysis. The strategic collaboration, announced in December 2025, gave Dr. Reddy's exclusive rights outside North America, Europe, Japan, and Greater China. Immunet will conduct an orderly study wind-down while reviewing data to determine next steps for the program.

12Mar 26

Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement

Dr. Reddy's Laboratories Ltd. announced a special window for re-lodgement of physical share transfer requests through newspaper advertisements published on March 12, 2026. The advertisements appeared in Business Standard and Nava Telangana in compliance with SEBI Regulation 47. The company notified both NSE and BSE about this initiative through official communication signed by Company Secretary K Randhir Singh.

12Mar 26

Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme

Dr. Reddy's Laboratories Limited allotted 10,275 equity shares of Re. 1/- each to eligible employees on March 12, 2026, under its Employee Stock Options Schemes from 2002 and 2007. The allotment increased the company's total issued shares to 83,46,54,295 and total issued share capital to Rs. 83,46,54,295/-. The newly issued shares rank pari passu with existing shares and carry no lock-in restrictions.

10Mar 26

Dr. Reddy's Laboratories Elevates M S Madhu Sundar as Global Head of Quality and PV

Dr. Reddy's Laboratories has elevated M S Madhu Sundar as Global Head of Quality and PV, effective April 1, 2026. The Board approved this appointment based on committee recommendations, with Madhu Sundar transitioning from his current role as Head Global Manufacturing FTO Oral Solid Dosages & Operational Excellence. He will also join as Senior Management Personnel and Member of Management Council. The company announced additional role changes for other senior management personnel including M V Ramana as CEO Global Generics and Sanjay Sharma as Chief Operating Officer.

06Mar 26

Dr. Reddy's Laboratories Receives USFDA VAI Classification for Srikakulam Facility

Dr. Reddy's Laboratories has successfully completed the USFDA regulatory review process for its formulations manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and officially closed the inspection, allowing the facility to continue operations while addressing any identified concerns voluntarily.

26Feb 26

Dr Reddy's Semaglutide Launch Timeline Faces Potential Delays in Canada

Dam Capital has flagged potential delays in Dr Reddy's Laboratories' semaglutide launch in Canada, with Sandoz projecting a H2 CY26 timeline instead of the earlier H1 CY26 guidance. The regulatory approvals for both Brazil and Canada markets may face delays, potentially impacting the pharmaceutical company's international expansion strategy and market entry plans for the diabetes medication.

25Feb 26

Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action

Dr. Reddy's Laboratories has successfully concluded a multi-year SEC investigation that began with anonymous complaints in November 2020 regarding alleged improper payments to healthcare professionals in Ukraine and other countries. The company maintained full cooperation throughout the process and received official communication on February 23, 2026, confirming the SEC's decision not to recommend any enforcement action at this time.

17Feb 26

Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes

Dr. Reddy's Laboratories allotted 12,665 equity shares to employees on February 17, 2026, under two employee stock option schemes from 2002 and 2007. The shares were exercised at three different price points, with the highest at Rs. 735.80/- per share. This allotment increased the company's total issued shares to 83,46,44,020, with corresponding share capital of Rs. 83,46,44,020/-. The newly issued shares rank equally with existing shares and are immediately tradeable across all exchanges where the company is listed.

24Jan 26

Dr. Reddy's Russian Subsidiary Receives Tax Audit Decision with INR 24.50 Million Penalty

Dr. Reddy's Laboratories disclosed that its Russian subsidiary received a tax audit decision on January 23, 2026, from Russian tax authorities, resulting in a penalty of Rub 20.09 million (INR 24.50 million) for VAT levy on reclassified marketing services. The company stated there is no material impact on its financials or operations and will evaluate filing a response to the tax authority.

21Jan 26

Dr. Reddy's Laboratories Reports Q3FY26 Results with 4.4% Revenue Growth

Dr. Reddy's Laboratories reported Q3FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY, with net profit of ₹12,098 million. Growth was driven by branded businesses and favorable forex, offsetting lower Lenalidomide sales. The company achieved several strategic milestones including collaboration with Immutep and launch of Hevaxin® vaccine, while managing the impact of India's New Labour Codes implementation.

08Jan 26

Dr Reddy's Labs to Release Q3FY26 Results on January 21 with Earnings Call

Dr Reddy's Laboratories has scheduled its Q3FY26 results announcement for January 21, 2026, covering the quarter ended December 31, 2025. The company will host an earnings call at 19:30 PM IST (9:00 AM ET) following the board meeting, with comprehensive stakeholder access through multiple channels including website presentations and call transcripts.

01Jan 26

Dr. Reddy's Laboratories Receives GST Orders Worth ₹8.38 Crores in Penalties for FY 2018-19 to FY 2022-23

Dr. Reddy's Laboratories disclosed receiving five GST orders from Visakhapatnam authority imposing total penalties of ₹8.38 crores for FY 2018-19 to FY 2022-23. The orders, received on December 31, 2025, allege excess input tax credit claims under APGST Act 2017. The company states no material impact on operations and plans to evaluate filing an appeal.

01Jan 26

Dr. Reddy's Swiss Arm Gets USFDA Complete Response Letter For AVT03 Biosimilar

Dr. Reddy's Laboratories announced that its Swiss subsidiary received a Complete Response Letter from USFDA for the AVT03 biosimilar application, which is a proposed denosumab biosimilar to Prolia and Xgeva. The regulatory setback stems from observations during a pre-license inspection of manufacturing partner Alvotech's facility in Reykjavik, highlighting compliance issues that need to be addressed before approval.

15Dec 25

Dr. Reddy's Receives USFDA Form 483 for Srikakulam Plant with Five Observations

The US Food and Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at Dr Reddy's Laboratories' Srikakulam plant. The regulatory body issued a Form 483 citing five specific concerns observed during the inspection. Form 483 indicates potential violations of food and drug laws and regulations. Dr Reddy's is required to respond with corrective actions within 15 working days to address these concerns and maintain compliance with US regulatory standards.

12Dec 25

High Court Refuses to Stay Dr Reddy's Export of Semaglutide to International Markets

A High Court bench has declined to issue a stay order against Dr Reddy's Laboratories' export of semaglutide to certain international markets. This decision allows the pharmaceutical company to continue its overseas sales of the important diabetes and weight management medication, maintaining its supply chain and commercial commitments internationally.

12Dec 25

Dr. Reddy's Sets Science-Based Net Zero Targets by 2045

Dr Reddy's Laboratories has announced science-based Net Zero climate targets, aiming to achieve zero greenhouse gas emissions across its value chain by FY2045. The company has set near-term and long-term goals, including an 80% reduction in Scope 1 & 2 emissions and a 51.6% reduction in Scope 3 emissions per INR value added by FY2030. Dr Reddy's plans to be coal-and furnace oil-free by FY26 and source 68% of its power from renewable energy by FY25. This commitment makes Dr Reddy's the first Indian pharmaceutical company to set such ambitious climate targets.

11Dec 25

Dr. Reddy's Laboratories Records ₹32.40 Crore NSE Block Trade at ₹1,251.50 Per Share

Dr. Reddy's Laboratories recorded a significant NSE block trade worth ₹32.40 crores involving 258,904 shares at ₹1,251.50 per share. The transaction reflects substantial institutional activity and strategic investment decisions in the pharmaceutical major. Such block trades typically indicate meaningful capital deployment by institutional investors and can influence trading dynamics.

03Dec 25

Dr. Reddy's Laboratories Sees Rs. 113.93 Crore Block Trade on NSE

A significant block trade of 888,017 shares of Dr Reddy's Laboratories was executed on the National Stock Exchange (NSE) at Rs. 1,283.00 per share. The total transaction value amounted to Rs. 113.93 crores. This large-volume trade indicates substantial institutional or bulk investor activity in the pharmaceutical company's stock.

11Nov 25

Dr. Reddy's Laboratories Thwarts Cyber Fraud Attempt, Confirms No Financial Loss

Dr Reddy's Laboratories successfully prevented a cyber fraud attempt involving vendor email impersonation. The hackers tried to redirect a legitimate payment of approximately Rs 2.16 crore. The company's internal teams and banking partners detected the fraud early, implemented preventive measures, and froze the funds promptly. No financial loss occurred to the company or the vendor. The incident was not categorized as material under SEBI regulations, and thus did not require formal disclosure.

10Nov 25

Dr. Reddy's Global Head of Biologics Jayanth Sridhar to Step Down

Jayanth Sridhar, Global Head of Biologics at Dr Reddy's Laboratories, has resigned to pursue opportunities outside the company. His resignation is effective January 31, 2026, with a transition period until then. The company has notified stock exchanges as per SEBI regulations. No immediate information on a successor or impacts on the biologics division has been provided.

09Nov 25

Dr. Reddy's Laboratories Falls Victim to Rs 2.16 Crore Email Fraud

Dr Reddy's Laboratories lost Rs 2.16 crore in a sophisticated cyber fraud scheme. Fraudsters used email spoofing to impersonate executives from Group Pharmaceutical Ltd and divert a payment. The scam involved creating a fake email address similar to the legitimate one, differing only in capitalization. Group Pharmaceutical Ltd has filed an FIR with Bengaluru City Cyber Crime Police. The case is registered under IT Act sections for identity theft and cheating by personation. The accused's location has been traced to Vadodara, Gujarat.

01Nov 25

Dr Reddy's Stock Dips 4% Following Health Canada's Non-Compliance Notice for Semaglutide Generic

Dr Reddy's Laboratories experienced a 4% decline in share price following a notice of non-compliance from Health Canada for its Abbreviated New Drug Application (ANDA) for Semaglutide, a weight management medication. The setback impacts the company's significant investments in infrastructure for Semaglutide and its plans to be a market leader. This incident is part of a broader trend of regulatory challenges faced by Indian pharmaceutical companies in complex drug applications.

30Oct 25

Dr. Reddy's Q2 Revenue Grows 9.8% Despite Lenalidomide Pressure; EBITDA Margin at 26.7%

Dr Reddy's Laboratories reported Q2 consolidated revenues of ₹8,805 crores ($992 million), up 9.8% year-over-year. Profit After Tax increased by 14% YoY to ₹1,437 crores ($162 million). North America Generics revenue declined 16% YoY due to price erosion in key products, while European Generics revenue grew 115% YoY. India business revenue increased 13% YoY, and Emerging Markets revenue rose 14% YoY. The company launched new products across markets, acquired Stugeron® brand, and made progress in biosimilars and novel drugs development. Dr Reddy's maintains focus on growth strategies despite challenges in the US generics market.

29Oct 25

Dr Reddy's Faces Regulatory Hurdle in Canada for Semaglutide Submission

Dr Reddy's Laboratories received a Notice of Non-Compliance from Canadian regulators regarding its Abbreviated New Drug Submission for Semaglutide Injection. The notice requests additional information and clarifications. Dr Reddy's plans to respond within the stipulated time frame and remains confident in their product's quality and safety. This setback could delay the company's entry into the Canadian market with its semaglutide product, a medication used for diabetes management and weight loss.

27Oct 25

Dr. Reddy's Q2 Profit Rises to ₹1,347 Crore, Outlines Future Financial Targets

Dr Reddy's Laboratories reported a 7.33% year-over-year increase in net profit to ₹1,347.00 crore for Q2 FY24, surpassing market estimates. Revenue grew by 9.94% to ₹8,828.00 crore. However, EBITDA declined slightly to ₹2,000.00 crore, with margins compressing to 22.77%. The company projects SG&A costs at 28-30% of sales, R&D expenses around 7%, and aims for 25% EBITDA margins by FY27. Dr Reddy's plans to secure Semaglutide approvals in 87 countries within 12-15 months and expects 20-25% gross margins in pharmaceutical services and active ingredients.

24Oct 25

Dr. Reddy's Clarifies No Partnership with Eli Lilly for Tirzepatide, Projects Growth Through Biosimilars and Global Expansion

Dr Reddy's Laboratories has officially stated it has no plans to collaborate with Eli Lilly for launching Tirzepatide, a diabetes medication, in India. The company expects continued growth driven by its biosimilars portfolio, API pipeline, and global expansion strategy. Dr Reddy's reported a 22% return on capital employed and anticipates growth from Europe and emerging markets, with high-margin products expected to enhance long-term profitability.

24Oct 25

Dr. Reddy's Q2FY26: Revenue Grows 9.8% YoY, Profit Up 14% Despite Challenges

Dr Reddy's Laboratories reported a 9.8% YoY revenue growth to ₹8,805.00 crore and a 14% increase in profit to ₹1,437.00 crore in Q2FY26. Global Generics revenue grew 10% YoY, with strong performance in Europe (+138% YoY) offsetting a 13% decline in North America. PSAI segment revenue increased 12% YoY. The company faced challenges with gross margin declining 492 bps YoY due to reduced Lenalidomide sales and price erosion in North America. Key developments include the acquisition of the STUGERON® portfolio and launches of novel drugs in India.

23Oct 25

Dr Reddy's Q2 Results Preview: Analysts Project 11-18% PAT Growth Despite US Challenges

Dr Reddy's Laboratories is set to announce Q2 FY24 results on October 24. Analysts project steady performance with 11-18% YoY PAT growth and 10-14% YoY revenue growth. Strong performance in India and Europe is expected to offset US market challenges. EBITDA margins may face slight compression due to pricing pressures in the US and product mix changes. The company's diversified geographical presence is seen as a buffer against market-specific challenges.

23Oct 25

Dr. Reddy's Srikakulam Facility Receives FDA Inspection Report with Voluntary Action Indicated Status

Dr Reddy's Laboratories' Srikakulam facility has received a 'voluntary action indicated' (VAI) status in the USFDA's establishment inspection report. This outcome allows the facility to continue operations without immediate regulatory intervention, though some voluntary actions may be needed to address minor issues. The VAI status is generally viewed positively, potentially boosting investor confidence and demonstrating the company's ability to meet stringent regulatory standards.

21Oct 25

Dr. Reddy's Srikakulam Facility Receives 'Voluntary Action Indicated' Classification from USFDA

Dr Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh. The inspection, conducted on July 18, 2025, has been classified as 'Voluntary Action Indicated (VAI)' and officially closed. This classification allows the company to address minor concerns voluntarily without further regulatory intervention. The company disclosed this development to stock exchanges in compliance with SEBI regulations.

12Oct 25

Dr. Reddy's and Zydus Recall Pharmaceutical Products in US Market

Dr. Reddy's Laboratories is recalling 571 vials of Succinylcholine Chloride Injection due to out-of-specification results in stability testing. Zydus Pharmaceuticals is recalling over 1,500 boxes of Entecavir tablets (912 bottles of 0.5mg and 600 bottles of 1mg) due to failed impurity/degradation specifications. Both recalls are classified as Class II by the FDA, indicating potential temporary or medically reversible health consequences.

24Sept 25

Dr Reddy's to Offer Generic HIV Prevention Drug at $40 Annually by 2027

Dr Reddy's Laboratories and Hetero Labs are set to introduce generic versions of lenacapavir, a revolutionary HIV prevention drug, priced at approximately $40 per year. Distribution is scheduled to begin in 2027. The companies received royalty-free licenses from Gilead Sciences to manufacture and distribute the drug in 120 low- and lower-middle-income countries. The original drug, marketed as Yeztugo by Gilead Sciences, costs around $28,000 annually in the US. This initiative, supported by global health organizations, could potentially benefit millions in low-income countries and significantly impact global HIV prevention efforts.

22Sept 25

Dr. Reddy's Secures Positive CHMP Opinion for Denosumab Biosimilar AVT03

Dr Reddy's Laboratories has received a positive opinion from the EMA's CHMP for AVT03, a proposed biosimilar of denosumab. AVT03 is a biosimilar candidate to Prolia® and Xgeva®. Upon approval, it will be marketed as Acvybra® and Xbonzy®. The company plans to commercialize AVT03 in Europe and the UK, with Alvotech handling development and manufacturing. This advancement expands Dr Reddy's biosimilar portfolio, potentially increasing access to osteoporosis treatment and offering cost savings to healthcare systems.

18Sept 25

Dr. Reddy's Promoters Transfer 20.58% Stake to Family Trusts for Succession Planning

Dr Reddy's Laboratories' promoters, Satish Reddy Kallam and G V Prasad, transferred a combined 20.58% stake to their respective family trusts on September 17, 2025. Satish Reddy Kallam transferred 9.06% to VSD Family Trust, reducing his stake from 10.27% to 1.21%. G V Prasad transferred 11.51% to GVP Family Trust, reducing his stake to 0%. The transfer, involving 17,17,26,540 equity shares, was part of a succession planning initiative. Despite individual changes, the aggregate promoter group holding remains at 26.64%. The transfer was conducted under a SEBI exemption for succession planning purposes.

17Sept 25

Dr. Reddy's Prepares for Generic Weight-Loss Drug Ingredients and Launches Novel Molecule Tegoprazan

Dr Reddy's Laboratories is preparing to supply ingredients for generic versions of popular weight-loss medications. The company has also launched Tegoprazan, a novel molecule for acid-related gastrointestinal diseases, in India under the brand name PCAB®. Tegoprazan showed 99% efficacy in treating GERD patients during clinical trials. The drug is approved in 21 countries and is under registration in several others. This dual focus demonstrates Dr Reddy's commitment to addressing diverse healthcare needs in the pharmaceutical industry.

16Sept 25

Dr. Reddy's Launches Novel Acid Blocker Tegoprazan in India Under Brand PCAB

Dr Reddy's Laboratories has introduced Tegoprazan, a next-generation potassium-competitive acid blocker (P-CAB), in India under the brand name PCAB®. The drug is designed to treat acid-related gastrointestinal diseases, including GERD and gastric ulcers. In clinical trials, 99% of GERD patients achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries and aims to address the needs of approximately 38% of the Indian population affected by acid peptic diseases. This launch is part of Dr Reddy's exclusive partnership with South Korea's HK inno.N Corporation.

15Sept 25

Dr Reddy's Laboratories Receives FDA Form 483 with Five Observations at Bachupally Biologics Facility

The US FDA issued a Form 483 with five observations following a Pre-Approval Inspection at Dr Reddy's Laboratories' Bachupally biologics facility. The company will need to address these observations, which could potentially impact product approvals and operations. Dr Reddy's is expected to develop a corrective action plan and respond to the FDA's concerns promptly.

13Sept 25

Dr. Reddy's Receives Form 483 with Five Observations Following USFDA Inspection at Hyderabad Biologics Facility

Dr Reddy's Laboratories' biologics manufacturing facility in Bachupally, Hyderabad underwent a USFDA Pre-Approval Inspection from September 4-12. The inspection resulted in a Form 483 with five observations, which the company has committed to address within the stipulated timeline. This inspection follows a previous one in October 2023. Separately, Dr Reddy's acquired Janssen's Stugeron portfolio for $50.50 million, covering 18 markets across Asia-Pacific and EMEA regions. The company reported strong Q1 financial results with revenue at ₹8,542.00 crore and net profit at ₹1,417.80 crore.

11Sept 25

Dr. Reddy's Expands CNS Portfolio with $50.5 Million Acquisition of Stugeron Brand

Dr Reddy's Laboratories has acquired the Stugeron brand and associated products from Janssen Pharmaceutica NV for $50.5 million. The deal covers 18 markets across APAC and EMEA regions, with India and Vietnam as key markets. Stugeron, an antihistamine used for treating vestibular disturbances and vertigo, holds a leading position in India's anti-vertigo market. This acquisition allows Dr Reddy's to enter the anti-vertigo segment and strengthen its CNS portfolio. The company plans to leverage its market access to expand Stugeron's reach, aligning with its goal of reaching over 1.5 billion patients by 2030. Dr Reddy's shares closed 0.87% higher following the announcement.

05Sept 25

Dr. Reddy's Reports 13% Revenue Growth in FY20, Declares Rs. 25 Final Dividend

Dr Reddy's Laboratories announced consolidated revenues of Rs. 17,460.00 crore for FY20, a 13% year-over-year growth. The Global Generics segment contributed Rs. 13,810.00 crore, growing 12%. North America Generics revenue reached Rs. 6,470.00 crore, up 8%, while India operations generated Rs. 2,890.00 crore, up 11%. Profit after tax was Rs. 1,950.00 crore. The company recommended a final dividend of Rs. 25.00 per equity share. An impairment charge of Rs. 1,680.00 crore was recorded. All facilities previously under FDA warning now have 'Voluntary Action Indicated' status.

03Sept 25

Dr Reddy's Laboratories May Benefit from Potential GST Exclusion on Cancer Medications

Dr Reddy's Laboratories could potentially benefit from a proposed change in the GST structure that might exclude cancer medications. This could lead to lower pricing of cancer drugs, improved market accessibility, and enhanced value of the company's oncology portfolio. The move could allow Dr Reddy's to adjust its pricing strategy and potentially reach a broader patient base. However, the benefits are contingent on the final decision regarding the GST exclusion for cancer medications.

28Aug 25

Dr Reddy's Secures Court Stay on Tax Reassessment, Cipla Recalls Asthma Medication in US

Dr Reddy's Laboratories secured an interim stay on income tax reassessment proceedings related to a merger, halting a potential ₹2,395.00 crore demand. Cipla is recalling over 20,000 packs of Ibuterol Sulfate Inhalation Aerosol in the US. Biocon Pharma received FDA tentative approval for Sitagliptin Tablets USP in three strengths for type 2 diabetes treatment.

26Aug 25

Dr. Reddy's Secures Interim Stay on Tax Reassessment, Expresses Optimism on GST Reforms

Dr Reddy's Laboratories has obtained an interim stay from the Telangana High Court on income tax reassessment proceedings related to its merger with Dr. Reddy's Holding Limited. The stay applies to both the order under Section 148A(3) and the reassessment notice under Section 148 of the Income-tax Act. Dr Reddy's believes there is no tax evasion from the merger and will take appropriate actions as needed. The merger scheme includes an indemnification clause protecting the company from potential liabilities.

08Aug 25

Dr. Reddy's Miryalaguda API Plant Receives USFDA VAI Classification, Inspection Closed

Dr Reddy's Laboratories' Active Pharmaceutical Ingredient (API) manufacturing facility in Miryalaguda, Telangana, has received a 'Voluntary Action Indicated' (VAI) classification from the United States Food and Drug Administration (USFDA) following an inspection. The company received an Establishment Inspection Report (EIR) from the USFDA, officially closing the inspection under 21 CFR 20.64(d)(3). K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy's, disclosed this development to the stock exchanges.

08Aug 25

Dr Reddys Laboratories Dissolves Wholly Owned Subsidiary Imperial Owners and Land Possessions

Dr Reddy's Laboratories announced the dissolution of its wholly owned subsidiary, Imperial Owners and Land Possessions Private Limited, following a voluntary liquidation process. The National Company Law Tribunal, Hyderabad Bench, approved the dissolution on August 5, 2025. Dr Reddy's stated that the liquidation will not materially impact its consolidated financial statements as Imperial was not a material subsidiary. The company has informed relevant stock exchanges in compliance with SEBI regulations.

29Jul 25

Dr. Reddy's Q1 Revenue Surges 11% YoY, EBITDA Margin at 26.7%

Dr Reddy's Laboratories reported consolidated revenues of ₹8,545.00 crores ($997.00 million) for Q1, up 11% year-over-year. The company achieved an EBITDA margin of 26.7% and profit after tax of ₹1,419.00 crores ($166.00 million). Performance varied across segments, with European Generics showing significant growth while North America Generics declined. Strategic initiatives include a biosimilar collaboration with Alvotech, expansion of the Nicotine Replacement Therapy business, and focus on complex generics and biosimilars. The company maintains a positive outlook, targeting an EBITDA margin of 25% or higher.

25Jul 25

Dr Reddy's Invests ₹565 Crore in Russian Subsidiary, Reports Strong Quarterly Results

Dr Reddy's Laboratories invested ₹565.40 crore for a 45.19% stake in its Russian subsidiary, DRL Russia, to support working capital needs. The company reported Q3 revenue of ₹8,542.00 crore, up from ₹7,672.70 crore year-over-year. Net profit increased to ₹1,417.80 crore from ₹1,392.00 crore, while EBITDA rose to ₹2,287.00 crore from ₹2,160.00 crore. However, EBITDA margin slightly decreased to 26.70% from 28.20%. The company's shares closed at ₹1,277.10, up 0.97%.

25Jul 25

Dr Reddy's Laboratories Invests ₹5.65 Billion in Russian Subsidiary

Dr Reddy's Laboratories has invested ₹5.65 billion (about $75 million) to acquire a 45.19% stake in its step-down wholly-owned subsidiary, Dr Reddy's Laboratories LLC, Russia (DRL Russia). The investment aims to strengthen the company's presence in the Russian market and support DRL Russia's working capital needs. DRL Russia has shown consistent growth, with its turnover increasing from ₹1,915 crore in FY2023 to ₹2,347 crore in FY2025. The investment was approved at the company's 41st Annual General Meeting.

24Jul 25

Dr. Reddy's Shareholders Approve G V Prasad's Re-appointment as Co-Chairman and Managing Director

Dr Reddy's Laboratories held its 41st Annual General Meeting on July 24, 2025. Shareholders approved G V Prasad's re-appointment as Co-Chairman and Managing Director for a five-year term from January 30, 2026, to January 29, 2031. Other key resolutions passed include adoption of financial statements, declaration of Rs. 8.00 dividend per equity share, approval of Cost Auditors' remuneration, and appointment of Secretarial Auditors. The AGM saw strong participation with 85 members attending via video conferencing, representing 22,33,11,552 shares.

24Jul 25

Dr. Reddy's Shares Rise Despite Missing Q1 Profit Estimates; Brokerages Mixed on Outlook

Dr Reddy's Laboratories reported Q2 consolidated net profit of Rs 1,418.00 crore, up 1.8% YoY but below estimates. Revenue rose 11.4% to Rs 8,572.00 crore, missing projections. Operating margins narrowed to 25.4%. The earnings miss was attributed to U.S. generics pricing pressure and lower operating leverage. Despite this, shares traded 2.53% higher. Brokerage reactions were mixed, with ratings ranging from 'Equal-weight' to 'Buy'. The company faces U.S. market headwinds but sees strength in branded markets and its Nicotine Replacement Therapy portfolio.

23Jul 25

Dr. Reddy's Reports 11% Revenue Growth in Q1, Expands Strategic Partnerships

Dr Reddy's Laboratories reported consolidated revenues of ₹85,452.00 million for Q1, an 11% year-over-year increase. Global Generics segment grew 10%, with Europe showing 142% growth. North America revenues declined 11% due to price erosion in key products. India market grew 11%, while PSAI segment increased 7%. The company expanded partnerships with Alvotech and Sanofi, and launched new products. R&D expenses were 7.3% of revenues. Despite challenges in the U.S. generics market, Dr Reddy's remains focused on strengthening its base business through pipeline delivery and productivity improvements.

23Jul 25

Dr. Reddy's Plans Global Expansion with Generic Weight-Loss Drugs

Dr Reddy's Laboratories plans to introduce generic versions of weight-loss medications across 87 countries, including Canada, India, and Brazil, in the coming year. The company aims to capitalize on the growing global demand for these treatments by making them more accessible and affordable. Additionally, Dr Reddy's intends to appoint Deloitte Haskins & Sells LLP as its Statutory Auditors for five years, starting from the financial year 2026-27, subject to approvals.

23Jul 25

Dr. Reddy's Reports 11% Revenue Growth to ₹8,545 Crore in Q1 FY26, Driven by NRT Portfolio and Branded Markets

Dr Reddy's Laboratories reported consolidated revenues of ₹8,545 crore for Q1 FY26, up 11% year-over-year. Global Generics segment grew 10%, with Europe showing 142% growth. North America revenues declined 11% due to price erosion in key products. Profit after Tax increased 2% YoY to ₹1,418 crore. The company expanded partnerships for biosimilars and launched new products in India. Management remains focused on strengthening the base business amid challenges in the U.S. generics market.

22Jul 25

Dr Reddy's Q1 Results Preview: Analysts Expect Revenue Growth Up to 19%, FDA Inspection Concludes Positively

Dr Reddy's Laboratories is set to announce Q1 results on July 23. Analysts project mixed earnings with PAT estimates ranging from ₹1,399.00 crore to ₹1,659.00 crore, and revenue estimates between ₹8,491.00 crore and ₹9,094.00 crore. Growth drivers include steady domestic demand, strong US sales, Nicotinell acquisition, and favorable currency movements. The company received a positive FDA inspection outcome for its API facility in Middleburgh, New York, classified as 'Voluntary Action Indicated'.

21Jul 25

Dr. Reddy's New York API Facility Receives USFDA Approval with VAI Status

Dr Reddy's Laboratories' Active Pharmaceutical Ingredient (API) facility in Middleburgh, New York, has received an Establishment Inspection Report (EIR) from the USFDA with a 'Voluntary Action Indicated' (VAI) status. The inspection is officially closed under 21 CFR 20.64(d)(3). This outcome allows the facility to continue operations without significant regulatory hurdles, indicating ongoing compliance with FDA standards. The company views this as a positive development, reinforcing its position in the global pharmaceutical market.

20Jul 25

Dr Reddy's Andhra Pradesh Plant Receives Seven FDA Observations

Dr Reddy's Laboratories' manufacturing facility in Andhra Pradesh has received seven observations from the U.S. Food and Drug Administration (USFDA) following a recent inspection. These observations, typically issued on Form 483, indicate potential regulatory compliance issues at the facility. The company is expected to respond to the FDA with corrective and preventive actions to address the identified issues. This development may impact Dr Reddy's operations and regulatory standing in the United States, a key pharmaceutical market.

18Jul 25

FDA Inspection of Dr. Reddy's Srikakulam Facility Yields 7 Observations

The USFDA completed an inspection of Dr. Reddy's Laboratories' formulations manufacturing facility in Srikakulam, Andhra Pradesh, from July 10 to July 18, 2025. The inspection, which included both GMP and Pre-Approval assessments, resulted in a Form 483 with seven observations. Dr. Reddy's has committed to addressing these issues within the stipulated timeline. The company's response and ability to resolve these observations will be crucial for maintaining its standing with the USFDA and ensuring continued operations at the Srikakulam facility.

17Jul 25

Dr Reddy's Laboratories Anticipates Positive Q1 Results Despite Revlimid Concerns

Dr Reddy's Laboratories is expected to report positive revenue and profit figures in its Q1 results on July 23, despite concerns about potential revenue decline from its cancer drug Revlimid. The anticipated growth reflects the company's strong market position and diverse product portfolio. The positive outlook suggests successful mitigation of risks associated with any single product line and highlights the company's effective diversification strategy.

12Jun 25

Dr Reddy's Laboratories: Eight Arrested in ₹2 Crore Semaglutide Theft Case

Dr Reddy's Laboratories experienced a significant theft at its Srikakulam warehouse, with 460 grams of Semaglutide, an anti-diabetic drug worth over ₹2 crore, stolen. Eight individuals, including four company employees, were arrested. Police recovered 440 grams of genuine Semaglutide and 460 grams of counterfeit powder. A separate theft of palladium acetate worth ₹60 lakh is also under investigation. The incidents raise concerns about internal security and may lead to a security overhaul, potential financial and reputational impacts, and increased regulatory scrutiny for the company.

06Jun 25

Dr. Reddy's Partners with Alvotech for Keytruda Biosimilar Development

Dr. Reddy's Laboratories has formed a strategic partnership with Alvotech for the co-development, manufacturing, and commercialization of a biosimilar to Keytruda (pembrolizumab) for global markets. The collaboration aims to accelerate development timelines and expand market reach. Both companies will share costs, responsibilities, and retain global commercialization rights, with some exceptions. This partnership could potentially increase accessibility and affordability of cancer treatments, as Keytruda is a widely used immunotherapy drug for various types of cancers.

05Jun 25

Dr. Reddy's Partners with Alvotech for Biosimilar Development, Following Semaglutide Setback

Dr. Reddy's Laboratories has formed a strategic partnership with Alvotech to co-develop a biosimilar candidate for Keytruda (pembrolizumab), a cancer treatment drug. The collaboration involves shared development costs and joint commercialization rights. This move comes after Dr. Reddy's faced challenges with semaglutide sales in India. The partnership aims to expand Dr. Reddy's presence in the oncology biosimilars market, potentially increasing access to important cancer therapies.

02Jun 25

Dr Reddy's Laboratories Faces Rs 2,395 Crore Tax Demand from Income Tax Department

Dr Reddy's Laboratories has received a tax demand of Rs 2,395.00 crore from the Income Tax Department for the assessment year 2020-21. The demand is related to the merger between Dr Reddy's Laboratories and Dr Reddy's Holdings. The company believes the amalgamation was conducted in compliance with all applicable laws and does not anticipate any material impact on its financial position or operations. Dr Reddy's is likely to engage with tax authorities to address this matter.

26May 25

Dr. Reddy's Telangana API Facility Receives USFDA Form 483 with Two Observations

The U.S. Food and Drug Administration (USFDA) has issued a Form 483 with two observations following a Good Manufacturing Practice (GMP) inspection at Dr. Reddy's Laboratories' CTO-5 API facility in Telangana. The company has not yet released an official statement. This regulatory notice requires Dr. Reddy's to address potential violations of manufacturing standards, although it doesn't necessarily imply immediate regulatory action. The company is expected to respond with a corrective action plan within 15 business days.

19May 25

Dr Reddy's Laboratories Reports Strong Q4 Growth, Eyes Biosimilars and Semaglutide

Dr Reddy's Laboratories posted 20% YoY revenue growth and 21% YoY net profit increase in Q4. The company is strategically focusing on biosimilars and Semaglutide portfolio for growth beyond 2026. Plans include global launch of GLP-1 (Semaglutide) this year and Abatacept submission by end of 2025. Despite reduced target prices, analysts project 6-18% upside potential.

17May 25

US FDA Issues Form 483 with Two Observations for Dr. Reddy's New York API Facility

The FDA completed a GMP inspection at Dr. Reddy's API facility in Middleburgh, New York, resulting in a Form 483 with two observations. The company acknowledges the observations and plans to address them within the stipulated timeline. While not implying immediate regulatory action, this development signals potential areas for improvement in compliance with FDA standards.

12May 25

Dr. Reddy's Q4 Results: Profit Surges 22%, but Misses Estimates; Analysts Cautious

Dr Reddy's Laboratories reported a 22% YoY increase in Q4FY25 net profit to ₹1,594.00 crore, with revenue growing 20% to ₹8,506.00 crore. EBITDA at ₹2,475.00 crore missed analyst estimates by 10%. Strong growth was seen in North America (9%), Europe (145%), and India (16%). Despite revenue growth, the company faced margin pressure with OPM decreasing to 23.22%. Management guides for double-digit revenue growth and 25% EBITDA margin in FY26, but analysts remain cautious due to competitive pressures and declining margins.

09May 25

Dr. Reddy's Laboratories Expands Global Footprint with New Subsidiary in Vietnam

Dr. Reddy's Laboratories has established a new wholly-owned subsidiary in Vietnam through its Swiss subsidiary, Dr. Reddy's Laboratories SA. The new entity, 'Dr. Reddy's Laboratories (Vietnam) Company Limited', aims to strengthen the company's presence in the Southeast Asian pharmaceutical market. This strategic move aligns with Dr. Reddy's global expansion strategy and its focus on tapping into emerging markets with growing healthcare needs.

09May 25

Dr Reddy's Laboratories Announces Rs 8 Per Share Final Dividend for FY 2024-25

Dr Reddy's Laboratories Ltd. has recommended a final dividend of Rs 8.00 per share for the fiscal year 2024-25. The record date for determining eligible shareholders is set for July 10, 2024. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.

09May 25

Dr Reddy's Laboratories: Q4 Profit Surges 22%, Revenue Climbs 20%

Dr. Reddy's Laboratories reported strong Q4 FY2024-25 results, with consolidated revenue increasing 20% to ₹8,506.00 crore and net profit rising 22% to ₹1,594.00 crore. EBITDA grew by 58.90% to ₹2,975.00 crore, with the EBITDA margin expanding by 510 basis points to 29.10%. The company also announced a dividend, reflecting its strong financial performance.

08May 25

Dr Reddy's Laboratories Sets Date for Q4 Results, Dividend Announcement

Dr Reddy's Laboratories will release its Q4 and FY 2024-25 financial results on May 9, 2025. The board will consider recommending a final dividend. A trading window closure for insiders is set from March 25 to May 11, 2025. An earnings call is scheduled for 7:30 p.m. IST on May 9, 2025.

28Apr 25

Dr Reddy's Expands Partnership with Sanofi, Set to Launch RSV Drug Beyfortus in India

Dr Reddy's Laboratories has expanded its partnership with Sanofi Healthcare, gaining exclusive rights to promote and distribute Beyfortus, a novel drug for preventing Respiratory Syncytial Virus (RSV) in newborns and infants, in India. The launch is expected in the second quarter of the current fiscal year. This move strengthens Dr Reddy's position in the pediatric pharmaceutical segment and addresses a critical need in pediatric healthcare.

21Apr 25

Dr. Reddy's Laboratories Sees Significant Block Trade on NSE

A significant block trade of 137,711 shares of Dr. Reddy's Laboratories occurred on the National Stock Exchange. The transaction was executed at Rs. 1,169.80 per share, totaling Rs. 16.11 crores. This large-scale trade has drawn attention from market observers, though its specific implications for the company's stock remain unclear.

16Apr 25

Dr. Reddy's Dismisses Speculation on Sanofi's Lantus Acquisition

Dr. Reddy's Laboratories has officially addressed market speculation regarding its potential acquisition of Sanofi's insulin brand, Lantus. The company stated there is no material event to disclose at this time, in response to a news item in The Economic Times. K Randhir Singh, Company Secretary and Compliance Officer, emphasized the company's policy of not commenting on market speculations and assured compliance with SEBI regulations for disclosing material events.

15Apr 25

Dr Reddy's Laboratories Refutes Claims of 25% Workforce Cost Reduction

Dr Reddy's Laboratories has officially refuted claims of a 25% reduction in workforce costs. The company issued a statement to stock exchanges on April 14, 2025, categorically denying the information published in a Business Standard article dated April 13, 2025. The pharmaceutical giant emphasized its commitment to transparency and regulatory compliance, stating that it promptly discloses material information as required by SEBI Listing Regulations. Dr Reddy's also noted that it does not comment on market speculations and currently has no event requiring disclosure under Regulation 30.

14Apr 25

Dr Reddy's Laboratories Denies Reports of Major Workforce Restructuring

Dr Reddy's Laboratories has refuted recent reports of a significant workforce restructuring plan. The company denied claims of implementing a downsizing initiative to cut workforce costs by 25%, asking high-earning executives to resign, or offering a voluntary retirement scheme for R&D employees. This denial suggests that the company's organizational structure and operational focus remain unchanged.

11Apr 25

Dr. Reddy's Laboratories Sees Significant Block Trade on NSE

A significant block trade of 365,549 shares of Dr. Reddy's Laboratories Ltd occurred on the National Stock Exchange. The shares were traded at Rs. 1,122.95 each, totaling Rs. 41.05 crore. This large-scale transaction has drawn attention in the market, potentially signaling shifts in institutional holdings or investor sentiment towards the multinational pharmaceutical company.

28Mar 25

Dr. Reddy's Lab Expands Footprint in Colombia with Exclusive Bio-thera Deal

Dr. Reddy's Laboratories has entered an exclusive commercialization agreement with Bio-thera for BAT2206 and BAT2506 in Colombia. Dr. Reddy's gains exclusive commercial rights for BAT2206, while Bio-thera retains responsibility for development, manufacturing, and supply of both products. This strategic move aims to strengthen Dr. Reddy's presence in the Colombian pharmaceutical market and expand its product portfolio in South America.

27Mar 25

Dr. Reddy's Expands Biosimilar Footprint in Southeast Asia through Partnership with Bio-Thera

Dr. Reddy's Laboratories has entered into an exclusive commercialization agreement with Chinese biotechnology company Bio-Thera Solutions for a biosimilar product in Southeast Asia. This strategic move aims to strengthen Dr. Reddy's presence in the region's growing biosimilar market. While specific product details remain undisclosed, the partnership is expected to leverage Dr. Reddy's expertise in drug commercialization and Bio-Thera's innovative pipeline.

22Mar 25

Dr. Reddy's Laboratories Completes Sale of Louisiana Subsidiary, Announces Board Meeting

Dr. Reddy's Laboratories has completed the sale of its Louisiana subsidiary, including the Shreveport manufacturing facility, on March 21, 2025. The company also announced a board meeting on May 9, 2025, to approve financial results for FY 2024-25 and consider dividend recommendations. A trading window closure is set from March 25 to May 11, 2025, in compliance with SEBI regulations.

21Mar 25

Dr. Reddy's Laboratories Sets Date for Q4 and FY 2024-25 Financial Results

Dr. Reddy's Laboratories will hold a board meeting on May 9, 2025, to approve financial results for Q4 and FY 2024-25, and consider recommending a final dividend. The company has announced a trading window closure from March 25 to May 11, 2025, in compliance with SEBI regulations.

18Mar 25

Dr. Reddy's and Alvotech's Biosimilar Application Accepted by FDA

The U.S. FDA has accepted a Biologic License Application (BLA) for AVT03, a proposed biosimilar to Prolia® and Xgeva®, jointly developed by Dr. Reddy's Laboratories and Alvotech. This acceptance marks a significant step in Dr. Reddy's strategy to expand its biosimilar portfolio, potentially opening new market opportunities in the treatment of osteoporosis and skeletal-related events in cancer patients. The application will undergo further FDA review before any final approval decision.

17Mar 25

Dr Reddy's Laboratories Initiates Recall of Mislabeled Levetiracetam Injection in US Market

Dr Reddy's Laboratories has initiated a recall for a specific batch of Levetiracetam in 0.75% Sodium Chloride Injection in the United States due to a critical labeling error. The affected batch, lot number A1540076, was distributed between November 4-6, 2024. The mislabeling poses potential health risks including double dosing and adverse effects. No adverse events have been reported so far. The company is taking proactive measures to ensure patient safety and demonstrates commitment to regulatory compliance.

Dr Reddys Laboratories

1,287.20

-35.70

(-2.70%)

1 Year Returns:+8.73%

Industry Peers

Sun Pharmaceutical

1,823.50

(+0.84%)

Divis Laboratories

6,619.50

(+1.80%)

Torrent Pharmaceuticals

4,251.80

(+1.59%)

Cipla

1,335.00

(+1.94%)

Dr Reddys Laboratories

1,287.20

(-2.70%)

Lupin

2,348.80

(+1.89%)

Mankind Pharma

2,257.80

(+0.49%)

Zydus Life Science

902.35

(+1.17%)

Aurobindo Pharma

1,376.00

(-0.97%)

Glenmark Pharmaceuticals

2,393.70

(-0.52%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104